The Venture Capital Podcast with Fexingo: VCs, Term Sheets, and Startup Investing

Episode 117 dives into the growing venture capital bet on nuclear energy to power AI data centers. Lucas and Luna break down a specific case: the $300 million round for Last Energy, a modular nuclear reactor startup backed by Founders Fund and a16z. They explore why VCs are moving beyond traditional clean tech into nuclear, the economics of small modular reactors versus gas peakers, and how the hyperscalers' insatiable energy demand is reshaping infrastructure investing. With recent data showing NVDA down 1.7% and PLTR up 6% this week, the hosts connect the dots between AI hardware bets and the energy supply chain needed to run it. No prior knowledge of nuclear engineering required — just curiosity about where the smart money is going.

#NuclearEnergy #VCInvesting #DataCenters #LastEnergy #SmallModularReactors #CleanTech #AIInfrastructure #VentureCapital #EnergyTransition #StartupFunding #Business #Technology #FexingoBusiness #BusinessPodcast #NuclearPower #InvestmentTrends #StartupEcosystem #InfrastructureInvesting

Keep every episode free: buymeacoffee.com/fexingo

In July 2026, BP closed its corporate venture capital arm, a move that surprised many in the startup world. Lucas and Luna unpack the reasons behind the shutdown, what it says about Big Oil's relationship with innovation, and how other corporate VCs are adapting. They discuss the tension between strategic investments and financial returns, and why BP's decision might signal a broader shift in how energy giants approach external innovation. With specific data on BP's portfolio and comparisons to peers like Shell and Chevron, this episode offers a clear-eyed look at the end of an era in corporate venturing.

#BP #CorporateVentureCapital #CVC #BigOil #EnergyTransition #VentureCapital #Innovation #StartupInvesting #BPVentures #OilAndGas #CleanTech #StrategicInvesting #FexingoBusiness #BusinessPodcast #Podcast #Business #Technology #VentureCapitalPodcast

Keep every episode free: buymeacoffee.com/fexingo

In this episode of The Venture Capital Podcast, Lucas and Luna explore the growing venture capital interest in sustainable materials startups. They anchor on Lululemon's recent $30 million Series A investment in Syntetica, a nylon-recycling company, to discuss how corporates and VCs are betting on circular economy technologies. The hosts examine the market dynamics driving these investments, the challenges of scaling novel materials, and the role of strategic corporate investors alongside traditional VCs. They contrast the narrative with the broader tech market, noting how the S&P 500 has been up 18% year-to-date, but clean-tech venture funding remains selective. Lucas breaks down the economics of recycled nylon versus virgin nylon, and Luna questions whether these deals can generate venture-scale returns or are better suited for corporate balance sheets. The conversation also touches on how VCs are using offtake agreements to de-risk early-stage material science bets. Tune in for a specific, data-driven look at one of the quieter corners of venture capital in 2026.

#SustainableMaterials #VentureCapital #Lululemon #Syntetica #NylonRecycling #CircularEconomy #Cleantech #CorporateVenture #SeriesA #OfftakeAgreements #MaterialScience #ClimateTech #ESG #BusinessAndTechnology #Business #Podcast #FexingoBusiness #BusinessPodcast

Keep every episode free: buymeacoffee.com/fexingo

In this episode of The Venture Capital Podcast, Lucas and Luna explore why venture capitalists are increasingly backing AI-native robotics startups. They dive into the recent $200 million Series C of Covariant, a company that builds brain-like software for warehouse robots, and discuss how the shift from rule-based automation to self-learning robots is reshaping logistics, manufacturing, and even home services. Lucas explains how advances in large language models and multimodal AI are enabling robots to generalize across tasks — a key factor driving VC interest. The hosts also touch on the broader market context, including the recent rally in tech stocks and the cooling of ARK Innovation ETF, which has shifted investor focus from speculative biotech to tangible AI hardware. With concrete examples and data points, this episode gives listeners a clear understanding of the new thesis: robots that learn, not just repeat. This episode is ideal for anyone interested in venture capital, robotics, AI, or the future of labor.

#VentureCapital #Robotics #AINative #Covariant #WarehouseAutomation #LogisticsTech #ArtificialIntelligence #StartupInvesting #TermSheets #SeriesC #GeneralPurposeRobots #LaborMarket #Automation #BusinessAndTechnology #FexingoBusiness #BusinessPodcast #TechTrends #Fundraising

Keep every episode free: buymeacoffee.com/fexingo

In this episode, Lucas and Luna dive into the trend of venture capitalists betting big on AI-powered drug discovery, anchored by the news that an OpenAI researcher is launching a startup valued at $2 billion. They explore why AI-first biotech is attracting massive funding, how it differs from traditional pharma R&D, and what the risks are. Plus, they touch on market signals like the ARKG genomics ETF's recent dip and the broader tech rally led by Meta and NVIDIA. A focused conversation on the intersection of artificial intelligence and biology.

#AIDrugDiscovery #VentureCapital #Biotech #OpenAI #MilesWang #DrugDevelopment #PharmaAI #Genomics #ARKG #StartupValuation #VCRisk #BusinessPodcast #Technology #FexingoBusiness #BusinessPodcast #Podcast #2026 #AIStartups

Keep every episode free: buymeacoffee.com/fexingo

This episode of The Venture Capital Podcast dives into how venture capitalists are using insurance risk models to back startups in 2026. Lucas and Luna explore the rise of parametric insurance for climate tech, the use of insurtech to underwrite supply chain risks, and how startups are leveraging insurance-linked securities. They reference recent market moves like COIN's volatility and PLTR's defense contracts to ground the discussion in current events. The conversation also touches on regulatory challenges and the potential for insurance to unlock new venture asset classes.

#VentureCapital #Insurance #Startups #RiskModels #Insurtech #ParametricInsurance #ClimateTech #SupplyChain #VentureDebt #COS #PLTR #DefenseTech #2026 #FexingoBusiness #BusinessPodcast #Technology #Investing #StartupFunding

Keep every episode free: buymeacoffee.com/fexingo

Episode 111 of The Venture Capital Podcast drills into the fastest-moving corner of ad tech: AI-native advertising platforms. Lucas and Luna unpack how VCs are pouring capital into startups that use generative AI to create, optimize, and personalize ads in real time — and why this threatens the duopoly of Google and Meta. They anchor the conversation in the recent $439 million raise by video-generation startup PixVerse, whose valuation soared past $2 billion, and connect it to broader trends in inference costs, targeting without cookies, and the rise of autonomous ad agents. With Meta's stock up 6.7% in the last five days and Google's down 4%, the hosts ask whether the market is pricing in disruption or just noise. Specific data, real term-sheet structures, and a look at the startups VCs are chasing.

#VentureCapital #AIAgents #AdTech #GenerativeAI #DigitalAdvertising #StartupFunding #PixVerse #VideoGeneration #InferenceCosts #ProgrammaticAdvertising #Meta #Google #Duopoly #TermSheets #Business #Technology #FexingoBusiness #BusinessPodcast

Keep every episode free: buymeacoffee.com/fexingo

Lucas and Luna explore how venture capital is flowing into insurtech startups that use alternative data and AI to underwrite risk for small businesses and gig workers. With traditional insurers pulling back from certain markets, VCs see a $500 billion opportunity for new risk models. Lucas breaks down a specific deal: a $150 million Series B for a startup called BufferRisk that uses real-time payroll and customer reviews to price liability insurance for independent contractors. Luna questions whether the data models can avoid bias and regulatory pitfalls. They discuss how this fits into the broader trend of VCs betting on infrastructure for the gig economy, and why the recent IPO of Lemonade competitor LadderLife signals investor appetite. The conversation touches on how macro uncertainty and rising interest rates are driving insurers to raise premiums, creating openings for agile startups. A natural, specific look at how risk is being reinvented as a venture asset class.

#Insurtech #VentureCapital #StartupRisk #AlternativeData #GigEconomy #Underwriting #BufferRisk #InsuranceTech #BusinessAndTechnology #FexingoBusiness #BusinessPodcast #LadderLife #AIUnderwriting #LiabilityInsurance #RegTech #Fintech #VCInvesting #DataDriven

Keep every episode free: buymeacoffee.com/fexingo

In 2026, more venture-backed startups are turning to Employee Ownership Trusts (EOTs) as an alternative exit—not just for mature companies, but for growth-stage firms. Lucas and Luna break down the mechanics of an EOT, why VCs are getting involved, and what it means for founders who want liquidity without selling to private equity. They walk through the fiscal incentives, the governance trade-offs, and the specific numbers behind recent deals, including how one mid-stage SaaS company structured a $150 million EOT with VC participation. If you're a founder or operator wondering whether an EOT could work for your company, this episode gives you the framework to decide.

#EmployeeOwnershipTrusts #VentureCapital #StartupExits #EOT #Business #Technology #FounderLiquidity #PrivateEquity #ESOP #Governance #SaaS #ExitStrategy #VCDeals #EmployeeOwnership #FexingoBusiness #BusinessPodcast #TheVentureCapitalPodcast #StartupStrategy

Keep every episode free: buymeacoffee.com/fexingo

Episode 108 of The Venture Capital Podcast explores why venture capital is pouring into longevity biotech—not just anti-aging, but treating biological aging as a disease. Lucas and Luna break down the $7.1 billion invested in longevity startups in 2025, the rise of epigenetic reprogramming, and how VCs are thinking about revenue models in a field that takes decades. Using live data from July 12, 2026, including the ARKG biotech ETF down 5.2% in five days, they discuss whether the hype matches the science.

#LongevityBiotech #VentureCapital #AgingResearch #EpigeneticReprogramming #BiotechStartups #HealthcareInvesting #Business #Technology #FexingoBusiness #BusinessPodcast #StartupInvesting #VCInvestments #AntiAging #TechBio #DrugDevelopment #BiotechETF #RKGBiotech #CellularReprogramming

Keep every episode free: buymeacoffee.com/fexingo